Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report.

Literature DB >> 24061910

Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report.

Alfredo Adán¹, Marina Mesquida, Victor Llorenç, Consuelo Modesto.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2013 PMID： 24061910 DOI： 10.1007/s00417-013-2466-5

Source DB: PubMed Journal: Graefes Arch Clin Exp Ophthalmol ISSN： 0721-832X Impact factor: 3.117

× No keyword cloud information.

6 in total

Review 1. Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases.

Authors: Lisa Kaly; Itzhak Rosner
Journal: Best Pract Res Clin Rheumatol Date: 2012-02 Impact factor: 4.098

2. The clinical course of juvenile idiopathic arthritis-associated uveitis in childhood and puberty.

Authors: Maretta Hoeve; Viera Kalinina Ayuso; Nicoline E Schalij-Delfos; Leonoor I Los; Aniki Rothova; Joke H de Boer
Journal: Br J Ophthalmol Date: 2012-03-07 Impact factor: 4.638

3. Vasoproliferative tumours of the retina.

Authors: H Heimann; N Bornfeld; O Vij; S E Coupland; N E Bechrakis; U Kellner; M H Foerster
Journal: Br J Ophthalmol Date: 2000-10 Impact factor: 4.638

4. Retinal vasoproliferative tumors: surgical management and histological findings.

Authors: F Irvine; N O'Donnell; E Kemp; W R Lee
Journal: Arch Ophthalmol Date: 2000-04

5. Retinal vasoproliferative tumors: comparative clinical features of primary vs secondary tumors in 334 cases.

Authors: Carol L Shields; Swathi Kaliki; Saad Al-Dahmash; Duangnate Rojanaporn; Shripaad Y Shukla; Brad Reilly; Jerry A Shields
Journal: JAMA Ophthalmol Date: 2013-03 Impact factor: 7.389

6. Tocilizumab treatment for refractory uveitis-related cystoid macular edema.

Authors: Alfredo Adán; Marina Mesquida; Victor Llorenç; Gerard Espinosa; Blanca Molins; Maria V Hernández; Laura Pelegrín
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2013-07-27 Impact factor: 3.117

6 in total

5 in total

Review 1. IL-6 blockade in the management of non-infectious uveitis.

Authors: Giuseppe Lopalco; Claudia Fabiani; Jurgen Sota; Orso Maria Lucherini; Gian Marco Tosi; Bruno Frediani; Florenzo Iannone; Mauro Galeazzi; Rossella Franceschini; Donato Rigante; Luca Cantarini
Journal: Clin Rheumatol Date: 2017-05-20 Impact factor: 2.980

Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report.

Review 1. Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases.

2. The clinical course of juvenile idiopathic arthritis-associated uveitis in childhood and puberty.

3. Vasoproliferative tumours of the retina.

4. Retinal vasoproliferative tumors: surgical management and histological findings.

5. Retinal vasoproliferative tumors: comparative clinical features of primary vs secondary tumors in 334 cases.

6. Tocilizumab treatment for refractory uveitis-related cystoid macular edema.

Review 1. IL-6 blockade in the management of non-infectious uveitis.

Review 2. Interleukin-6 blockade in ocular inflammatory diseases.

Review 3. Treatment of uveitis associated with juvenile idiopathic arthritis.

Review 4. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.

Review 5. Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review.